Medicare to cover GLP-1 drugs for weight loss starting July 1. Here’s what to know.

Medicare to Cover GLP-1 Weight Loss Drugs Starting July 1

Medicare to cover GLP 1 drugs - Beginning July 1, 2026, Medicare beneficiaries will gain access to GLP-1 medications for weight loss, with a $50 monthly copay through a temporary program designed to improve affordability. This initiative, known as the Medicare GLP-1 Bridge, expands coverage for specific weight-loss drugs from Eli Lilly and Novo Nordisk, including Zepbound, Foundayo, and Wegovy. The move reflects growing recognition of GLP-1 drugs as a valuable tool for combating obesity, a condition linked to significant health risks and rising healthcare costs.

Program Structure and Legal Framework

The Medicare GLP-1 Bridge program utilizes a provision in the Inflation Reduction Act to create a short-term solution for drug coverage. According to Juliette Cubanski, vice president and director of Medicare policy at the Kaiser Family Foundation, this approach allows the federal government to cover the cost of GLP-1 drugs without requiring permanent legislative action. "This temporary program gives Medicare beneficiaries access to weight-loss medications for a limited period, addressing immediate needs while awaiting long-term policy decisions," she noted. The initiative will run from July 1, 2026, through December 31, 2027, after which its continuation depends on CMS or Congress.

"The program’s temporary nature means there’s still uncertainty about the future of GLP-1 drug coverage under Medicare," Cubanski explained. "However, it provides a critical opportunity for patients who meet the clinical criteria to benefit from these medications at a reduced cost."

Eligibility and Clinical Requirements

To qualify for the Medicare GLP-1 Bridge program, beneficiaries must have Medicare Part D coverage and meet specific clinical conditions. The primary criteria include a BMI of at least 35, which indicates severe obesity, or a BMI of 30 or higher with comorbidities such as heart failure, uncontrolled hypertension, or chronic kidney disease. Patients with a BMI of 27 or more and conditions like prediabetes, a history of heart attack or stroke, or symptomatic peripheral artery disease are also eligible. Prior authorization is required to confirm that the medication is prescribed for weight loss, not for other purposes like diabetes or sleep apnea.

Drug Coverage and Pricing

Medicare will cover Eli Lilly’s Foundayo, a daily oral weight-loss medication, and Zepbound KwikPen, a weekly injectable option. Novo Nordisk’s Wegovy, available in both injectable and pill forms, is also included. These drugs are typically expensive, with monthly costs exceeding $350 without insurance. Under the Bridge program, beneficiaries will pay a fixed $50 copay, which does not count toward their deductible or annual out-of-pocket limit. This structured cost approach aims to make weight-loss treatments more accessible while preserving financial flexibility for other healthcare needs.

Benefits and Patient Impact

The introduction of GLP-1 drug coverage under Medicare is expected to have a profound effect on patients struggling with obesity. By reducing out-of-pocket expenses, the program may encourage more individuals to pursue medication-assisted weight loss, particularly those with chronic conditions that complicate traditional approaches. "This coverage can make a meaningful difference for patients who might otherwise delay or forgo treatment due to high costs," said Cubanski. Additionally, the program could serve as a model for future policies, demonstrating the potential of GLP-1 drugs to improve health outcomes and reduce long-term healthcare expenditures.

Future Outlook and Policy Considerations

As of now, the Medicare GLP-1 Bridge program is set to expire at the end of 2027. Its extension will depend on the Centers for Medicare & Medicaid Services (CMS) or Congress making a decision on the matter. Policymakers may evaluate the program’s success based on factors like patient utilization, cost savings, and health improvements. The inclusion of GLP-1 drugs in Medicare coverage also raises questions about their role in broader healthcare strategies, as their effectiveness in weight management has been supported by numerous clinical trials.

Experts emphasize that while the program is a step forward, it is not a permanent solution. "The $50 copay is a vital aid, but we need to see sustained coverage and potential integration into Medicare’s standard benefits," Cubanski stated. With KFF estimating that up to 3.8 million beneficiaries could qualify for this coverage, the initiative highlights the growing intersection between obesity management and public health policy. As the trial period begins, patients and providers will closely monitor its impact and advocate for its continuation or expansion.